Novartis (NVS) said Monday that its radioligand therapy, Pluvicto, combined with standard care, significantly improved radiographic progression-free survival in a pre-specified interim analysis of a phase 3 trial for patients with a certain type of prostate cancer.
The drugmaker said a positive trend in overall survival was also observed.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。